The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans
Open accessAbstract
It has been reported that lactoferrin (LF) participates in the host immune response against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) invasion by enhancing NK cell activity and stimulating neutrophil aggregation and adhesion. We further investigated the role of LF in the entry of SARS pseudovirus into HEK293E/ACE2-Myc cells. Our results reveal that LF inhibits SARS pseudovirus infection in a dose-dependent manner. Further analysis suggested that LF was able to block the binding of spike protein to host cells at 4°C, indicating that LF exerted its inhibitory function at the viral attachment stage. However, LF did not disrupt the interaction of spike protein with angiotensin-converting enzyme 2 (ACE2), the functional receptor of SARS-CoV. Previous studies have shown that LF colocalizes with the widely distributed cell-surface heparan sulfate proteoglycans (HSPGs). Our experiments have also confirmed this conclusion. Treatment of the cells with heparinase or exogenous heparin prevented binding of spike protein to host cells and inhibited SARS pseudovirus infection, demonstrating that HSPGs provide the binding sites for SARS-CoV invasion at the early attachment phase. Taken together, our results suggest that, in addition to ACE2, HSPGs are essential cell-surface molecules involved in SARS-CoV cell entry. LF may play a protective role in host defense against SARS-CoV infection through binding to HSPGs and blocking the preliminary interaction between SARS-CoV and host cells. Our findings may provide further understanding of SARS-CoV pathogenesis and aid in treatment of this deadly disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Self-citationGuan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,031
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
Kuiken, T., Fouchier, R. A., Schutten, M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., Laman, J. D., de Jong, T., van Doornum, G., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13967-0 · Cited by 1,020
Lactoferrin: structure, function and applications
González-Chávez, S. A., Arévalo-Gallegos, S., & Rascón-Cruz, Q. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.07.020 · Cited by 759
Lactoferrin—a multifunctional protein with antimicrobial properties
Farnaud, S., & Evans, R. W. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00152-4 · Cited by 738
Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G., & Jiang, C. (2008) · Cell Research · doi:10.1038/cr.2008.15 · Cited by 707
Self-citationLambert, D. W., Yarski, M., Warner, F. J., Thornhill, P., Parkin, E. T., Smith, A. I., Hooper, N. M., & Turner, A. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505111200 · Cited by 694
Herpes simplex virus: receptors and ligands for cell entry
Spear, P. G. (2004) · Cellular Microbiology · doi:10.1111/j.1462-5822.2004.00389.x · Cited by 581
Baba, M., Snoeck, R., Pauwels, R., & de Clercq, E. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.11.1742 · Cited by 544
Simmons, G., Reeves, J. D., Rennekamp, A. J., Amberg, S. M., Piefer, A. J., & Bates, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306446101 · Cited by 543
Antimicrobial properties of lactoferrin
JENSSEN, H., & HANCOCK, R. (2009) · Biochimie · doi:10.1016/j.biochi.2008.05.015 · Cited by 509
Lactoferrin: Lactoferrin: an important host defence against microbial and viral attack
Valenti, P., & Antonini, G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5372-0 · Cited by 488
Antiviral activities of lactoferrin
van der Strate, B. W. A., Beljaars, L., Molema, G., Harmsen, M. C., & Meijer, D. K. F. (2001) · Antiviral Research · doi:10.1016/s0166-3542(01)00195-4 · Cited by 477
Schulze, A., Gripon, P., & Urban, S. (2007) · Hepatology · doi:10.1002/hep.21896 · Cited by 445
Lactoferrin: Molecular structure, binding properties and dynamics of lactoferrin
Baker, E. N., & Baker, H. M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5368-9 · Cited by 387
Cell surface heparan sulfate and its roles in assisting viral infections
Liu, J., & Thorp, S. C. (2002) · Medicinal Research Reviews · doi:10.1002/med.1026 · Cited by 311
Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome
Reghunathan, R., Jayapal, M., Hsu, L.-Y., Chng, H.-H., Tai, D., Leung, B. P., & Melendez, A. J. (2005) · BMC Immunology · doi:10.1186/1471-2172-6-2 · Cited by 300
Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry
Akhtar, J., & Shukla, D. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07402.x · Cited by 292
A structural framework for understanding the multifunctional character of lactoferrin
BAKER, E., & BAKER, H. (2009) · Biochimie · doi:10.1016/j.biochi.2008.05.006 · Cited by 279
Heparan sulfate proteoglycan as a plasma membrane carrier
Belting, M. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00031-8 · Cited by 273
Chen, J., & Subbarao, K. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141706 · Cited by 251
Cellular entry of the SARS coronavirus
Hofmann, H., & Pöhlmann, S. (2004) · Trends in Microbiology · doi:10.1016/j.tim.2004.08.008 · Cited by 237
Nègre, D., Mangeot, P.-E., Duisit, G., Blanchard, S., Vidalain, P.-O., Leissner, P., Winter, A.-J., Rabourdin-Combe, C., Mehtali, M., Moullier, P., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301292 · Cited by 206
Role of glycosaminoglycans for binding and infection of hepatitis B virus
Leistner, C. M., Gruen-Bernhard, S., & Glebe, D. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.01023.x · Cited by 191
Hepatitis C virus entry: potential receptors and their biological functions
Cocquerel, L., Voisset, C., & Dubuisson, J. (2006) · Journal of General Virology · doi:10.1099/vir.0.81646-0 · Cited by 191
Andersen, J. H., Osbakk, S. A., Vorland, L. H., Traavik, T., & Gutteberg, T. J. (2001) · Antiviral Research · doi:10.1016/s0166-3542(01)00146-2 · Cited by 182
Selinka, H.-C., Florin, L., Patel, H. D., Freitag, K., Schmidtke, M., Makarov, V. A., & Sapp, M. (2007) · Journal of Virology · doi:10.1128/jvi.00998-07 · Cited by 177
Sapp, M. J., & Bienkowska‐Haba, M. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07400.x · Cited by 161
Han, D. P., Lohani, M., & Cho, M. W. (2007) · Journal of Virology · doi:10.1128/jvi.00315-07 · Cited by 157
Groot, F., Geijtenbeek, T. B. H., Sanders, R. W., Baldwin, C. E., Sánchez‐Hernández, M., Floris, R., van Kooyk, Y., de Jong, E. C., & Berkhout, B. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.3009-3015.2005 · Cited by 154
Krähling, V., Stein, D. A., Spiegel, M., Weber, F., & Mühlberger, E. (2008) · Journal of Virology · doi:10.1128/jvi.01245-08 · Cited by 148
Virus Movements on the Plasma Membrane Support Infection and Transmission between Cells
Burckhardt, C. J., & Greber, U. F. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000621 · Cited by 145
Analysis of the Infectious Entry Pathway of Human Papillomavirus Type 33 Pseudovirions
Selinka, H., Giroglou, T., & Sapp, M. J. (2002) · Virology · doi:10.1006/viro.2001.1493 · Cited by 145
Puddu, P., Borghi, P., Gessani, S., Valenti, P., Belardelli, F., & Seganti, L. (1998) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(98)00066-1 · Cited by 142
Thorne, R. G., Lakkaraju, A., Rodriguez-Boulan, E. J., & Nicholson, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711345105 · Cited by 142
Murine Coronavirus with an Extended Host Range Uses Heparan Sulfate as an Entry Receptor
de Haan, C. A. M., Li, Z., Lintelo, E. G. T., Bosch, B., Haijema, B. J., & Rottier, P. J. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14451-14456.2005 · Cited by 137
Coronaviridaeand SARS-associated Coronavirus Strain HSR1
Vicenzi, E., Canducci, F., Pinna, D., Mancini, N., Carletti, S., Lazzarin, A., Bordignon, C., Poli, G., & Clementi, M. (2004) · Emerging infectious diseases · doi:10.3201/eid1003.030683 · Cited by 132
Yamauchi, K., Wakabayashi, H., Shin, K., & Takase, M. (2006) · Biochemistry and Cell Biology · doi:10.1139/o06-054 · Cited by 119
Superti, F., Siciliano, R. A., Rega, B., Giansanti, F., Valenti, P., & Antonini, G. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00178-7 · Cited by 112
Jenssen, H. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5228-7 · Cited by 108
Lactoferrin inhibits human papillomavirus binding and uptake in vitro
Drobni, P., Näslund, J., & Evander, M. (2004) · Antiviral Research · doi:10.1016/j.antiviral.2004.05.005 · Cited by 101
Marchetti, M., Trybala, E., Superti, F., Johansson, M. E., & Bergström, T. B. (2004) · Virology · doi:10.1016/j.virol.2003.09.029 · Cited by 100
Watanabe, R., Matsuyama, S., Shirato, K., Maejima, M., Fukushi, S., Morikawa, S., & Taguchi, F. (2008) · Journal of Virology · doi:10.1128/jvi.01412-08 · Cited by 93
Structural insights into SARS coronavirus proteins
Bartlam, M. G., Yang, H., & Rao, Z. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.10.004 · Cited by 91
Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo
BELJAARS, L., VANDERSTRATE, B., BAKKER, H., REKERSMIT, C., VANLOENENWEEMAES, A., WIEGMANS, F., HARMSEN, M., MOLEMA, G., & MEIJER, D. (2004) · Antiviral Research · doi:10.1016/j.antiviral.2004.05.002 · Cited by 78
Antiviral activity of human lactoferrin: inhibition of alphavirus interaction with heparan sulfate
Waarts, B.-L., Aneke, O. J. C., Smit, J. M., Kimata, K., Bittman, R., Meijer, D. K. F., & Wilschut, J. (2005) · Virology · doi:10.1016/j.virol.2005.01.010 · Cited by 72
Arai, T., Matsumoto, K., Saitoh, K., Ui, M., Ito, T., Murakami, M., Kanegae, Y., Saito, I., Cosset, F., Takeuchi, Y., et al. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1115-1121.1998 · Cited by 61
Heparan Sulphate Proteoglycans and Viral Vectors : Ally or Foe?
Vivès, R. R., Lortat‐Jacob, H., & Fender, P. (2006) · Current Gene Therapy · doi:10.2174/156652306775515565 · Cited by 50
Ammendolia, M. G., Pietrantoni, A., Tinari, A., Valenti, P., & Superti, F. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.09.002 · Cited by 39
Yeung, K. S., Yamanaka, G. A., & Meanwell, N. A. (2006) · Medicinal Research Reviews · doi:10.1002/med.20055 · Cited by 31
Copreni, E., Castellani, S., Palmieri, L., Penzo, M., & Conese, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1248 · Cited by 25
Electrostatic interactions in the early events of VSV infection
Conti, C., Mastromarino, P., Anna Riccioli, A., & Orsi, N. (1991) · Research in Virology · doi:10.1016/0923-2516(91)90023-v · Cited by 23
Lactoferrin inhibits early steps of human BK polyomavirus infection
Longhi, G., Pietropaolo, V., Mischitelli, M., Longhi, C., Conte, M. P., Marchetti, M., Tinari, A., Valenti, P., Degener, A. M., & Seganti, L. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.008 · Cited by 23
Cited by
Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., Kucher, N., Studt, J.-D., Sacco, C., Bertuzzi, A., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.024 · Cited by 2,054
Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W.-C., Wang, C.-B., & Bernardini, S. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1783198 · Cited by 1,514
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
Clausen, T. M., Sandoval, D. R., Spliid, C. B., Pihl, J., Perrett, H. R., Painter, C. D., Narayanan, A., Majowicz, S. A., Kwong, E. M., McVicar, R. N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.033 · Cited by 1,136
The human virome: assembly, composition and host interactions
Liang, G., & Bushman, F. D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00536-5 · Cited by 624
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications
McFadyen, J. D., Stevens, H., & Peter, K. (2020) · Circulation Research · doi:10.1161/circresaha.120.317447 · Cited by 592
Metadata
- Authors
- Lang, J., Yang, N., Deng, J., Liu, K., Yang, P., Zhang, G., & Jiang, C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-08-22
- Volume
- 6
- Issue
- 8
- Pages
- e23710
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1992344082
- Cited by
- 427
- References
- 56
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.